2nd affiliated hospital, School of Medicine, Zhejiang Universtiy, China Trials

2nd affiliated hospital, School of Medicine, Zhejiang Universtiy, China	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Yan, Min

NCT05035069: Efficacy and Safety of Ciprofol Compared to Propofol for Nonintubated General Anesthesia in Patients Undergoing TAVR

Not yet recruiting

RoW

Ciprofol, Propofol

Haisco Pharmaceutical Group Co., Ltd.

Anesthesia, General

02/22

RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting

366

RoW

RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda

RemeGen Co., Ltd.

Breast Cancer

06/24

12/24

NCT06254742: A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies

Not yet recruiting

107

RoW

HHPG-19K Injection

Jiangsu HengRui Medicine Co., Ltd.

Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk

05/24

06/24

NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting

360

RoW

PM8002, Nab-Paclitaxel, Placebo

Biotheus Inc.

Triple Negative Breast Cancer(TNBC)

07/27

07/28

TQB2102-III-01, NCT06561607: A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Not yet recruiting

542

RoW

TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Breast Cancer

01/27

12/28

HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer

Active, not recruiting

654

Europe, Canada, Japan, US, RoW

Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo

Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC

HER2 Positive Breast Cancer

05/25

10/27

FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting

314

RoW

Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Breast Cancer

07/25

01/26

OPTIMAL, NCT03315364 / 2020-000954-86: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Active, not recruiting

2/3

549

Europe, RoW

Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol®

Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd.

Recurrent or Metastatic Breast Cancer

02/24

12/25

RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting

2/3

301

RoW

RC48-ADC, RC48, Lapatinib, Capecitabine

RemeGen Co., Ltd.

Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases

07/24

12/24

DAP-Her-01, NCT04293276: Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer

Active, not recruiting

RoW

Pyrotinib, SHR6390

Henan Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd.

Metastatic Breast Cancer

08/21

05/23

TQB3616-II-01, NCT04773418: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting

120

RoW

TQB3616 capsules, Fulvestrant injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive, HER2-negative Advanced Breast Cancer

01/23

NCT05394285: A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast Cancer

Recruiting

RoW

Hetrombopag, rh-TPO

Henan Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd.

Breast Cancer

12/24

NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Recruiting

160

RoW

TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Atopic Dermatitis

03/24

NCT05336721: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Terminated

RoW

Chiauranib, capecitabine

Chipscreen Biosciences, Ltd.

Triple-negative Breast Cancer

10/24

11/24

NCT05328440: Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Recruiting

120

RoW

Pyrotinib Maleate, Pyrotinib, Dalpiciclib Isethionate Tablets, SHR6390, Inetetamab, Fulvestrant

Henan Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd.

Breast Neoplasms

06/24

01/26

NCT06458413: Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer

Recruiting

RoW

Utidelone Capsule Plus Capecitabine

Min Yan, MD, Beijing Biostar Pharmaceuticals Co., Ltd.

Breast Cancer Recurrent

06/25

12/25

NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Recruiting

RoW

SPH4336 Tablets

Shanghai Pharmaceuticals Holding Co., Ltd

Breast Cancer Brain Metastases

12/25

NCT06208410: A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Recruiting

1/2

306

RoW

JS105, Fulvestrant injection, Dalpiciclib Isetionate Tablets, Toripalimab Injection, Paclitaxel for Injection (Albumin Bound), Fluzoparib Capsules, Pyrotinib Maleate Tablets, Capecitabine Tablets

Risen (Suzhou) Pharma Tech Co., Ltd.

Advanced Solid Tumors

02/26

NCT06464055: A Study of GQ1010 in Subjects With Advanced Solid Tumors

Recruiting

1/2

260

RoW

Dose Escalation, Dose Expansion1, Dose Expansion2, Dose Expansion3, phase II

GeneQuantum Healthcare (Suzhou) Co., Ltd.

Advanced Malignant Solid Tumors

05/28

12/28

KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting

1/2

1300

Canada, US, RoW

SKB264

Klus Pharma Inc.

Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer

08/25

07/26

NCT06679036: A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients

Recruiting

1/2

300

RoW

HRS-2189, Fluvustat, HRS-8080, HRS-6209, HRS-1358

Shandong Suncadia Medicine Co., Ltd.

Advanced Unresectable or Metastatic Breast Cancer

10/26

12/26

NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Recruiting

1/2

1123

US, RoW

DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327

DualityBio Inc., BioNTech SE

Advanced Solid Tumor

06/25

NCT06846099: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903

Recruiting

174

RoW

RP903

Risen (Suzhou) Pharma Tech Co., Ltd.

Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Breast Cancer, Solid Tumor Cancer

12/25

TQB3915-I-01, NCT05416359: Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors

Recruiting

RoW

TQB3915 tablets

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Malignant Tumor

06/23

06/24

NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Recruiting

150

RoW

SPH5030 tablets

Shanghai Pharmaceuticals Holding Co., Ltd

HER2-positive Advanced Solid Tumors

12/25

NCT05414136: Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006

Completed

RoW

BAT1006, Recombinant humanized anti-HER2 monoclonal antibody for injection

Bio-Thera Solutions

Advanced Solid Tumor

06/24

NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

Recruiting

153

RoW

HRS-1167

Jiangsu HengRui Medicine Co., Ltd.

Advanced Solid Tumors

12/24

SHI, Qingyu

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Yan, Min

NCT05035069: Efficacy and Safety of Ciprofol Compared to Propofol for Nonintubated General Anesthesia in Patients Undergoing TAVR

Not yet recruiting

RoW

Ciprofol, Propofol

Haisco Pharmaceutical Group Co., Ltd.

Anesthesia, General

02/22

RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting

366

RoW

RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda

RemeGen Co., Ltd.

Breast Cancer

06/24

12/24

NCT06254742: A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies

Not yet recruiting

107

RoW

HHPG-19K Injection

Jiangsu HengRui Medicine Co., Ltd.

Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk

05/24

06/24

NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Recruiting

360

RoW

PM8002, Nab-Paclitaxel, Placebo

Biotheus Inc.

Triple Negative Breast Cancer(TNBC)

07/27

07/28

Not yet recruiting

542

RoW

TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Breast Cancer

01/27

12/28

HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Jan 2025 - Dec 2025: From MOUNTAINEER-02 trial in combination with Herceptin and Cyramza for metastatic HER2+ gastric cancer

Active, not recruiting

654

Europe, Canada, Japan, US, RoW

Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo

Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC

HER2 Positive Breast Cancer

05/25

10/27

FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting

314

RoW

Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Breast Cancer

07/25

01/26

OPTIMAL, NCT03315364 / 2020-000954-86: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Active, not recruiting

2/3

549

Europe, RoW

Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol®

Daehwa Pharmaceutical Co., Ltd., Daehwa pharmaceutical Co., Ltd.

Recurrent or Metastatic Breast Cancer

02/24

12/25

RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting

2/3

301

RoW

RC48-ADC, RC48, Lapatinib, Capecitabine

RemeGen Co., Ltd.

Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases

07/24

12/24

DAP-Her-01, NCT04293276: Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer

Active, not recruiting

RoW

Pyrotinib, SHR6390

Henan Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd.

Metastatic Breast Cancer

08/21

05/23

TQB3616-II-01, NCT04773418: A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Recruiting

120

RoW

TQB3616 capsules, Fulvestrant injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

HR-positive, HER2-negative Advanced Breast Cancer

01/23

NCT05394285: A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast Cancer

Recruiting

RoW

Hetrombopag, rh-TPO

Henan Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd.

Breast Cancer

12/24

NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Recruiting

160

RoW

TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Atopic Dermatitis

03/24

NCT05336721: A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Terminated

RoW

Chiauranib, capecitabine

Chipscreen Biosciences, Ltd.

Triple-negative Breast Cancer

10/24

11/24

NCT05328440: Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Recruiting

120

RoW

Pyrotinib Maleate, Pyrotinib, Dalpiciclib Isethionate Tablets, SHR6390, Inetetamab, Fulvestrant

Henan Cancer Hospital, Jiangsu HengRui Medicine Co., Ltd.

Breast Neoplasms

06/24

01/26

NCT06458413: Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer

Recruiting

RoW

Utidelone Capsule Plus Capecitabine

Min Yan, MD, Beijing Biostar Pharmaceuticals Co., Ltd.

Breast Cancer Recurrent

06/25

12/25

NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Recruiting

RoW

SPH4336 Tablets

Shanghai Pharmaceuticals Holding Co., Ltd

Breast Cancer Brain Metastases

12/25

NCT06208410: A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Recruiting

1/2

306

RoW

JS105, Fulvestrant injection, Dalpiciclib Isetionate Tablets, Toripalimab Injection, Paclitaxel for Injection (Albumin Bound), Fluzoparib Capsules, Pyrotinib Maleate Tablets, Capecitabine Tablets

Risen (Suzhou) Pharma Tech Co., Ltd.

Advanced Solid Tumors

02/26

NCT06464055: A Study of GQ1010 in Subjects With Advanced Solid Tumors

Recruiting

1/2

260

RoW

Dose Escalation, Dose Expansion1, Dose Expansion2, Dose Expansion3, phase II

GeneQuantum Healthcare (Suzhou) Co., Ltd.

Advanced Malignant Solid Tumors

05/28

12/28

KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting

1/2

1300

Canada, US, RoW

SKB264

Klus Pharma Inc.

08/25

07/26

NCT06679036: A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients

Recruiting

1/2

300

RoW

HRS-2189, Fluvustat, HRS-8080, HRS-6209, HRS-1358

Shandong Suncadia Medicine Co., Ltd.

Advanced Unresectable or Metastatic Breast Cancer

10/26

12/26

NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Recruiting

1/2

1123

US, RoW

DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327

DualityBio Inc., BioNTech SE

Advanced Solid Tumor

06/25

NCT06846099: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903

Recruiting

174

RoW

RP903

Risen (Suzhou) Pharma Tech Co., Ltd.

Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Breast Cancer, Solid Tumor Cancer

12/25

TQB3915-I-01, NCT05416359: Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors

Recruiting

RoW

TQB3915 tablets

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advanced Malignant Tumor

06/23

06/24

NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Recruiting

150

RoW

SPH5030 tablets

Shanghai Pharmaceuticals Holding Co., Ltd

HER2-positive Advanced Solid Tumors

12/25

NCT05414136: Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006

Completed

RoW

BAT1006, Recombinant humanized anti-HER2 monoclonal antibody for injection

Bio-Thera Solutions

Advanced Solid Tumor

06/24

NCT05473624: Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

Recruiting

153

RoW

HRS-1167

Jiangsu HengRui Medicine Co., Ltd.

Advanced Solid Tumors

12/24

SHI, Qingyu

No trials found



	Diseases Companies Products Productz Mechanisms of Action Sites